Features - Interviews

Filter

Current filters:

Interviews

Popular Filters

1 to 25 of 49 results

EXPERT VIEW: Utilizing supplementary protection certificates for active ingredients in the pharma industry

EXPERT VIEW: Utilizing supplementary protection certificates for active ingredients in the pharma industry

29-09-2014

Intellectual Property can be vital for the success of any pharmaceutical invention. It is very important…

EuropeInterviewsLegalPatentsPharmaceuticalUnited Kingdom

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

29-09-2014

Diabetes is a firm priority of UK-based pharma major AstraZeneca and is in no danger of being side-lined,…

AstraZenecaBydureonDiabetesForxigaInterviewsOnglyzaPharmaceuticalResearchUK

EXPERT VIEW: The Interim Exec Community calls for a ‘Conscious Coupling’ of RPOs and Interims Specialists

EXPERT VIEW: The Interim Exec Community calls for a ‘Conscious Coupling’ of RPOs and Interims Specialists

19-09-2014

Pharmaceutical companies have widely adopted strategies to outsource elements of their business operations,…

BoardroomGlobalInterviewsPharmaceuticalRecruitment

EyeForPharma Multichannel Marketing Summit 2014: Lundbeck's Tim White on customer interaction, apps and buzzwords

EyeForPharma Multichannel Marketing Summit 2014: Lundbeck's Tim White on customer interaction, apps and buzzwords

19-09-2014

Tim White is head of global customer interaction at Lundbeck. The Pharma Letter spoke to him at the EyeForPharma…

DenmarkInterviewsLundbeckMarkets & MarketingNeurologicalPharmaceutical

EXPERT VIEW: Pfizer and AstraZeneca, a marriage not to be – yet?

EXPERT VIEW: Pfizer and AstraZeneca, a marriage not to be – yet?

19-08-2014

Mergers and acquisitions may excite the markets and shareholders on both sides but their record of success…

GlobalInterviewsMergers & AcquisitionsPharmaceutical

In Focus: The role of big data in the drug development process

In Focus: The role of big data in the drug development process

15-08-2014

As big data plays an increasing role in drug development and clinical trials, The Pharma Letter’s Bethany…

Clinical researchInterviewsMedidataPharmaceuticalPharmaceutical sciencesResearchRichard YoungTechnological tools

Executive Q&A: Thomas Hein, SVP commercial and regulatory affairs, Hermes Pharma

Executive Q&A: Thomas Hein, SVP commercial and regulatory affairs, Hermes Pharma

28-07-2014

In an interview with The Pharma Letter, Thomas Hein, senior vice president of commercial and regulatory…

Dosage formsDrug DeliveryGermanyHermes PharmaInterviewsPharmaceutical

Executive Q&A: Nicholas Saccomano, CSO of Array BioPharma

Executive Q&A: Nicholas Saccomano, CSO of Array BioPharma

15-07-2014

In an interview with The Pharma Letter, Nicholas Saccomano, chief science officer of Array BioPharma,…

Array BioPharmaBiogen IdecBiotechnologyChief science officerHealth Medical PharmaInterviewsMelanomaOncologyProtein kinase inhibitorUSA

In Focus: Strong drivers will keep the pharma M&A pipeline bubbling

In Focus: Strong drivers will keep the pharma M&A pipeline bubbling

28-05-2014

The record start to 2014’s pharma M&A has been a welcome boost to a deal market that had been in the…

CancerGlobalInterviewsMergers & AcquisitionsPfizerPharmaceuticalPharmaceutical industryPharmaceutical sciences

Executive Q&A: Paul Higham, CEO of immatics

Executive Q&A: Paul Higham, CEO of immatics

27-05-2014

In an interview with The Pharma Letter, immatics chief executive Paul Higham discusses the company's…

BiotechnologyCancerGermanyHealth Medical Pharmaimmatics biotechnologiesImmunologyInterviewsMedicineOncologyVaccination

Executive Q&A: Bob Radie, chief executive and president of Egalet

Executive Q&A: Bob Radie, chief executive and president of Egalet

11-04-2014

In an interview with The Pharma Letter, Egalet Corporation’s chief executive Bob Radie discusses the…

AnalgesiaChemistryChief executiveCombination productsEgalet CorpEgalet CorporationInterviewsPharmaceuticalSevere chronic painUSA

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

11-04-2014

The full year report from Anglo-Swedish drug major AstraZeneca (LSE: AZN) in February was full of optimism.…

AstraZenecaInterviewsIressaOncologyPharmaceuticalUK

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

07-04-2014

Uptake of biosimilars in Europe has increased as a result of member states’ policies, according to…

BiosimilarsEuropeFilgrastimInterviewsMarkets & MarketingRegulationSandoz

EGA Biosimilars: European monitoring and global business opportunities

EGA Biosimilars: European monitoring and global business opportunities

07-04-2014

The spotlight was on the European uptake of biosimilars at the European Generic medicines Association’s…

BiosimilarsEuropeGlobalInterviewsMarkets & Marketing

Executive Q&A: Epigenomics’ chief executive Dr Thomas Taapken

Executive Q&A: Epigenomics’ chief executive Dr Thomas Taapken

01-04-2014

The Pharma Letter interviewed chief executive Dr Thomas Taapken about Epigenomics’ lead product, increasing…

BiotechnologyEpi proColonEpigenomicsGermanyInterviewsOncology

Interview: Arnaud Grunwald of Model N on taking a holistic approach to revenue management

Interview: Arnaud Grunwald of Model N on taking a holistic approach to revenue management

20-03-2014

As health care budgets are squeezed worldwide and access issues continue to make the headlines, the price…

GlobalInterviewsPharmaceuticalPricing

Executive Q&A: ADC Therapeutics’ chief executive Michael Forer

Executive Q&A: ADC Therapeutics’ chief executive Michael Forer

19-03-2014

In an interview with The Pharma Letter, CEO Michael Forer discusses ADC Therapeutics' developing pipeline…

ADC TherapeuticsBiotechnologyInterviewsNorthern EuropeOncology

Executive Q&A: Fibrotech's chief executive Darren Kelly

Executive Q&A: Fibrotech's chief executive Darren Kelly

18-03-2014

The Pharma Letter interviewed chief executive Darren Kelly about Fibrotech’s ethos and its lead product,…

AustraliaBiotechnologyFibrotechInterviewsNephrology and Hepatology

Pharma Summit: Merck’s European president Bruno Strigini highlights importance of innovation

Pharma Summit: Merck’s European president Bruno Strigini highlights importance of innovation

17-03-2014

The president of pharma giant Merck & Co’s (NYSE: MRK) operations in Europe and Canada Bruno Strigini…

Anti-viralsCanadaDiabetesEuropeInterviewsMerck & CoMK-3475OncologyPharmaceuticalRegulationUKVaccines

Pharma Summit: Sanofi president Elias Zerhouni calls for harmony and evolution in pharma

Pharma Summit: Sanofi president Elias Zerhouni calls for harmony and evolution in pharma

14-03-2014

Health care is a human right and the pharma industry must evolve to meet future challenges, claims Elias…

EuropeHealthcareInterviewsPharmaceuticalSanofi

Pharma Summit: Rethinking the future – new business models for pharma

Pharma Summit: Rethinking the future – new business models for pharma

14-03-2014

The way pharma works needs to change with an increasing focus on collaborations, sharing data and access…

HealthcareInterviewsLundbeckPfizerPharmaceuticalPricingUK

1 to 25 of 49 results

Back to top